Gut & MicrobiomeA Decade of Gut Microbiome Science Reviewed by Leading Gastroenterologists
A decade ago, the gut microbiome was a niche research interest. Now it sits at the center of modern medicine. This expert review from the British Society of Gastroenterology surveys the enormous progress made since their first panel publication: larger multi-center studies, better sequencing technologies like shotgun metagenomics, and standardized analysis pipelines have replaced early small-cohort work. New frontiers include the microbiome's role in early life development, vaccine effectiveness, and cancer immunotherapy response. Fecal microbiota transplant (FMT) is now an established treatment for recurrent C. difficile infection, with licensed products in several countries. Other therapies — probiotics, bacteriophages, nutritional interventions — remain promising but have yet to fully deliver. The panel concludes that the field is maturing, with its greatest near-term value lying in clinical diagnostics, prognostics, and targeted therapeutics.
